Review Article

The Journal of the Korean Rheumatism Association 2009; 16(3): 175-180

Published online September 30, 2009

© Korean College of Rheumatology

수술 전후 TNF Inhibitor의 사용

고혁재1ㆍ박성환2

가톨릭대학교 대전성모병원 류마티스내과1, 서울성모병원 류마티스내과2

TNF Inhibitor Use during the Perioperative Period

Hyeok Jae Ko1, Sung Hwan Park2

Division of Rheumatology, Daejeon St. Mary's Hospital, Daejeon1, Seoul St. Mary's Hospital2, The Catholic University of Korea, Seoul, Korea

Correspondence to : Sung Hwan Park

Abstract

Tumor necrosis factor (TNF) inhibitors are now established as therapeutic agents for treating active rheumatoid arthritis (RA) that is resistant to conventional drug treatment. However, TNF Inhibitors decrease resistance to infection, including unusual infections such as tuberculosis, and they have been shown to impair wound healing in an experimental setting. To date, there is limited data on patients with RA regarding their infections or the complications of surgery performed while taking TNF inhibitors and there is no professional consensus about this. This problem emphasizes a need for awareness and communication between patients, the rheumatologist and the surgeon when treating patients with RA. We reviewed the effects of TNF inhibitors on the incidence of surgical site infection (SSI) and the risk factors for SSIs after performing elective surgery in patients with RA. TNF inhibitors should not be used during the perioperative period until conclusive evidence to the contrary is available.

Keywords TNF inhibitor, Rheumatoid arthritis, Surgery

Article

Review Article

The Journal of the Korean Rheumatism Association 2009; 16(3): 175-180

Published online September 30, 2009

Copyright © Korean College of Rheumatology.

수술 전후 TNF Inhibitor의 사용

고혁재1ㆍ박성환2

가톨릭대학교 대전성모병원 류마티스내과1, 서울성모병원 류마티스내과2

TNF Inhibitor Use during the Perioperative Period

Hyeok Jae Ko1, Sung Hwan Park2

Division of Rheumatology, Daejeon St. Mary's Hospital, Daejeon1, Seoul St. Mary's Hospital2, The Catholic University of Korea, Seoul, Korea

Correspondence to:Sung Hwan Park

Abstract

Tumor necrosis factor (TNF) inhibitors are now established as therapeutic agents for treating active rheumatoid arthritis (RA) that is resistant to conventional drug treatment. However, TNF Inhibitors decrease resistance to infection, including unusual infections such as tuberculosis, and they have been shown to impair wound healing in an experimental setting. To date, there is limited data on patients with RA regarding their infections or the complications of surgery performed while taking TNF inhibitors and there is no professional consensus about this. This problem emphasizes a need for awareness and communication between patients, the rheumatologist and the surgeon when treating patients with RA. We reviewed the effects of TNF inhibitors on the incidence of surgical site infection (SSI) and the risk factors for SSIs after performing elective surgery in patients with RA. TNF inhibitors should not be used during the perioperative period until conclusive evidence to the contrary is available.

Keywords: TNF inhibitor, Rheumatoid arthritis, Surgery

JRD
Oct 01, 2024 Vol.31 No.4, pp. 191~263
COVER PICTURE
Ancestry-driven pathways for SLE-risk SNP-associated genes. The ancestry-driven key signaling pathways in Asians, Europeans, and African Americans were analyzed by enrichr (https://maayanlab.cloud/Enrichr/#libraries) using non-HLA SNP-associated genes. SLE: systemic lupus erythematosus, SNP: single-nucleotide polymorphism, JAK–STAT: janus kinase–signal transducers and activators of transcription, IFN: interferon gamma. (J Rheum Dis 2024;31:200-211)

Stats or Metrics

Share this article on

  • line

Related articles in JRD

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download